このエントリーをはてなブックマークに追加
ID 52796
フルテキストURL
著者
Fujii, K Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol Surg
Kurozumi, K Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol Surg
Ichikawa, T Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol Surg
Onishi, M Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol Surg
Shimazu, Y Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol Surg
Ishida, J Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol Surg
Chiocca, EA Brigham & Womens Hosp, Dept Neurosurg
Kaur, B Ohio State Univ, Dept Neurol Surg, Dardinger Lab Neurooncol & Neurosci
Date, I Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Neurol Surg ORCID Kaken ID publons researchmap
抄録
Oncolytic viral (OV) therapy has been considered as a promising treatment modality for brain tumors. Vasculostatin, the fragment of brain-specific angiogenesis inhibitor-1, shows anti-angiogenic activity against malignant gliomas. Previously, a vasculostatin-expressing oncolytic herpes simplex virus-1, Rapid Antiangiogenesis Mediated By Oncolytic virus (RAMBO), was reported to have a potent antitumor effect. Here, we investigated the therapeutic efficacy of RAMBO and cilengitide, an integrin inhibitor, combination therapy for malignant glioma. In vitro, tube formation was significantly decreased in RAMBO and cilengitide combination treatment compared with RAMBO or cilengitide monotherapy. Moreover, combination treatment induced a synergistic suppressive effect on endothelial cell migration compared with the control virus. RAMBO, combined with cilengitide, induced synergistic cytotoxicity on glioma cells. In the caspase-8 and -9 assays, the relative absorption of U87 Delta EGFR cell clusters treated with cilengitide and with RAMBO was significantly higher than that of those treated with control. In addition, the activity of caspase 3/7 was significantly increased with combination therapy. In vivo, there was a significant increase in the survival of mice treated with combination therapy compared with RAMBO or cilengitide monotherapy. These results indicate that cilengitide enhanced vasculostatin-expressing OV therapy for malignant glioma and provide a rationale for designing future clinical trials combining these two agents.
キーワード
cilengitide
glioma
oncolytic viral therapy
発行日
2013-08
出版物タイトル
Cancer Gene Therapy
20巻
8号
出版者
Nature Publishing Group
開始ページ
437
終了ページ
444
ISSN
0929-1903
NCID
AA12570566
資料タイプ
学術雑誌論文
関連URL
http://ousar.lib.okayama-u.ac.jp/metadata/52519
言語
English
著作権者
© Nature Publishing Group
論文のバージョン
author
査読
有り
DOI
Web of Science KeyUT